20251301_ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225 ...

EQS-News: Eckert & Ziegler SE / Key word (s): Alliance/Incoming Orders Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement 13.01.2025 / 10:00 CET/CEST The issuer ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and ITM Isotope Technologies Munich ...

Korea is set to begin domestic production of actinium-225 (Ac-225), a key raw material for next-generation cancer treatments, ...

Garching / Munich / Berlin, Germany, January 13, 2025 - ITM Isotope Technologies Munich SE(Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment o ...

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand ...

Actinium Pharmaceuticals ( (ATNM)) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to its investors. Actinium Pharmaceuticals, Inc.

(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) Monday announced a narrower loss for the third quarter. The September quarter loss was $11.6 million, compared to $13.3 million a year ago.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK (AP) — NEW YORK (AP) — Actinium Pharmaceuticals Inc. (ATNM) on Thursday reported a loss of $11.6 million in its third quarter. On a per-share basis, the New York-based company said it ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...